Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
Phase 3
55 Years
N/A
55 Years
N/A
Not Enrolling
Female
Cardiovascular Diseases, Breast Neoplasms
Female
Cardiovascular Diseases, Breast Neoplasms
Trial Information
Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
Inclusion Criteria:
- Postmenopausal women with established coronary heart disease or at risk for a major
coronary event.
Exclusion Criteria:
- Postmenopausal symptoms that required estrogen replacement therapy.
- Suspected or known history of breast or endometrial carcinoma.
- Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal
vein thrombosis.
- New York Heart Association classes III or IV heart failure.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Outcome Measure:
Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
United States: Food and Drug Administration
Study ID:
1865
NCT ID:
NCT00190593
Start Date:
June 1998
Completion Date:
November 2005
Related Keywords:
- Cardiovascular Diseases
- Breast Neoplasms
- Breast Neoplasms
- Neoplasms
- Cardiovascular Diseases
Name | Location |
|---|---|
| For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician | Minneapolis, Minnesota |
